Potential in vitro activity of kutapressin against Epstein-Barr virus

E. Rosenfeld, B. Salimi, M. R.G. O'Gorman, C. Lawyer, B. Z. Katz*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Background: Kutapressin (KU), a porcine liver extract with bradykinin-potentiating effects but no vitamin B 12 activity, has been used in the treatment of Herpes zoster. We examined a phenol-free preparation of this drug for in vitro activity against Epstein-Barr Virus (EBV). Materials and Methods; Immortalization- inhibition assays were used to assess EBV infectivity. Mitogen stimulation and cell viability assays and flow cytometry were used to assess the mechanism of drug activity. Results: Seventy-five hundred mcg/ml of KU blocked the infection of 2 x 105 human umbilical cord mononuclear cells when added together with two strains of EBV (B95-8 and FF41). Doses as low as 250 mcg/ml were occasionally effective as well. Unlike acyclovir, KU dose not inhibit viral DNA polymerase nor dose it appear to compete with EBV as it binds to its receptor on the B-cell surface. Conclusions: The mechanism whereby KU may inhibit EBV immoirtalization remains to be determined. KU, a drug which is safe in humans, deserves further study as an agent with potential to block EBV-induced immortalization of B-lymphocytes.

Original languageEnglish (US)
Pages (from-to)313-318
Number of pages6
JournalIn Vivo
Issue number3
StatePublished - 1996


  • Acyclovir
  • Epstein-Barr virus
  • Kutapressin

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology


Dive into the research topics of 'Potential in vitro activity of kutapressin against Epstein-Barr virus'. Together they form a unique fingerprint.

Cite this